Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cardiovascular Diseases 3Breast Neoplasms 3Metabolic Syndrome 2Sarcoidosis 1Rectal Neoplasms 1Obesity 1Non-alcoholic Fatty Liver Disease 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases, Interstitial 1Liver Cirrhosis 1Hodgkin Disease 1Fatigue 1Colorectal Neoplasms 1Cardiotoxicity 1Breast Diseases 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Blood Pressure × Clear all
NCT05108805 2025-03-27

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Vanderbilt-Ingram Cancer Center

Phase 4 Completed
25 enrolled 17 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡